share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K:諾和諾德-股票回購計劃
美股SEC公告 ·  07/29 07:52

Moomoo AI 已提取核心訊息

Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on May 6, 2024. As part of a larger 12-month share repurchase initiative with a budget of up to DKK 20 billion that started on February 6, 2024, the company has been buying back B shares. From May 7, 2024, to August 5, 2024, Novo Nordisk is set to repurchase B shares worth up to DKK 2.2 billion. The latest transactions, reported on July 29, 2024, show that since the last announcement on July 22, 2024, the company has acquired an additional 201,500 B shares, spending approximately DKK 181,490,215. This brings the total repurchased under the program to 2,086,287 B shares at a cost of DKK 1,980,536,332. Novo Nordisk now holds 12,186,327 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has been actively executing its share repurchase program, which was announced on May 6, 2024. As part of a larger 12-month share repurchase initiative with a budget of up to DKK 20 billion that started on February 6, 2024, the company has been buying back B shares. From May 7, 2024, to August 5, 2024, Novo Nordisk is set to repurchase B shares worth up to DKK 2.2 billion. The latest transactions, reported on July 29, 2024, show that since the last announcement on July 22, 2024, the company has acquired an additional 201,500 B shares, spending approximately DKK 181,490,215. This brings the total repurchased under the program to 2,086,287 B shares at a cost of DKK 1,980,536,332. Novo Nordisk now holds 12,186,327 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
領先全球醫療保健公司丹波諾絲克自2024年5月6日宣佈股票回購計劃以來,一直在積極執行此項計劃。作爲一個12個月總預算達200億丹麥克朗的更大規模的股票回購倡議的一部分,自2024年2月6日開始,該公司一直在回購B股。自2024年5月7日至8月5日,丹波諾絲克將回購價值達22億丹麥克朗的B股。最新交易情況於2024年7月29日公佈,顯示自7月22日上次公告以來,該公司已額外收購2015000億股,總計花費約181,490,215丹麥克朗。該計劃下總共回購了20862870億股,花費了1,980,536,332丹麥克朗。丹波諾絲克現持有121863270億股庫藏股,佔股本的0.3%。該公司股票在納斯達克哥本哈根交易所和紐約證交所上市。
領先全球醫療保健公司丹波諾絲克自2024年5月6日宣佈股票回購計劃以來,一直在積極執行此項計劃。作爲一個12個月總預算達200億丹麥克朗的更大規模的股票回購倡議的一部分,自2024年2月6日開始,該公司一直在回購B股。自2024年5月7日至8月5日,丹波諾絲克將回購價值達22億丹麥克朗的B股。最新交易情況於2024年7月29日公佈,顯示自7月22日上次公告以來,該公司已額外收購2015000億股,總計花費約181,490,215丹麥克朗。該計劃下總共回購了20862870億股,花費了1,980,536,332丹麥克朗。丹波諾絲克現持有121863270億股庫藏股,佔股本的0.3%。該公司股票在納斯達克哥本哈根交易所和紐約證交所上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息